Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Serum Levels of Neurofilament Light Are Increased Before Clinical Onset of MS

Publish date:: February 6, 2020

Key clinical point: Serum levels of NfL were increased at 6 years before clinical onset in patients who developed MS, compared with controls.

Major finding: The median serum NfL level was 16.7 pg/mL in cases and 15.2 pg/mL in controls.

Study details: A nested case-control study that included 120 military personnel with serum samples stored in a Defense Department repository.

Disclosures: The Swiss National Research Foundation and the National Institute of Neurologic Disorders and Stroke funded the study. Several of the investigators received fees from various drug companies that were unrelated to the study, and one researcher received grants from the National Institutes of Health during the study.

Citation:

Bjornevik K et al. JAMA Neurol. 2020;77(1):58-64.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,